Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC
Clinical trial NCT03654027 · UNKNOWN
Trial details
- NCT number
- NCT03654027
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-01
- Primary completion
- 2019-10-01
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.